List of NOVEL Health Strategies Publications

  1. Aggarwal S., Serbin M., Yonan C., PND12 CLINICAL EFFICACY OF VALBENAZINE AND DEUTETRABENAZINE FOR THE TREATMENT OF TARDIVE DYSKINESIA: INDIRECT TREATMENT COMPARISON OF RANDOMIZED CONTROLLED TRIALS, Value in Health (2019) 22 Supplement 2 (S272). Date of Publication: 1 May 2019
  2. Richardson P., Aggarwal S., Topaloglu O., Villa K.F., Corbacioglu S., Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), Bone Marrow Transplantation (2019). Date of Publication: 2019
  3. Richardson P., Aggarwal S., Topaloglu O., Villa K.F., Corbacioglu S., Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) (Bone Marrow Transplantation, (2019), 10.1038/s41409-019-0474-8), Bone Marrow Transplantation (2019). Date of Publication: 2019
  4. Corbacioglu S., Aggarwal S., Topaloglu O., Martin R., Villa K., Pooled analysis of defibrotide studies in pediatric patients treated for veno-occlusive disease/sinusoidal obstruction syndrome, Pediatric Blood and Cancer (2018) 65 Supplement 2 (S223). Date of Publication: 1 Nov 2018
  5. Aggarwal S., Serbin M., Yonan C., Meta-analysis of randomized controlled trials of valbenazine and deutetrabenazine efficacy for treatment of tardive dyskinesia, Journal of Managed Care and Specialty Pharmacy (2018) 24:10 A (S49-S50). Date of Publication: 1 Oct 2018
  6. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay and costs in patients with Crohn's disease: Analysis of us national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S83). Date of Publication: 1 May 2018
  7. Aggarwal S., Kumar S., Topaloglu O., Hospital lenght of stay and costs in patients with post operative wound infection: Analysis of US national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses, Value in Health (2018) 21 Supplement 1 (S154). Date of Publication: 1 May 2018
  8. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay, seasonality and costs in patients with influenza infection: Analysis of us national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses, Value in Health (2018) 21 Supplement 1 (S154-S155). Date of Publication: 1 May 2018
  9. Aggarwal S., Kumar S., Topaloglu O., Hospital lenght of stay and costs in patients with urinary track infections: Analysis of US national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses, Value in Health (2018) 21 Supplement 1 (S267). Date of Publication: 1 May 2018
  10. Aggarwal S., Kumar S., Topaloglu O., Hospital lenght of stay and costs in patients with acute myeloid leukemia: Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S23). Date of Publication: 1 May 2018
  11. Aggarwal S., Topaloglu O., Kumar S., Using real-world evidence for health technology assessment submissions: Lessons and insights from review of NICE's technology assessment reports (2016-2017), Value in Health (2018) 21 Supplement 1 (S7). Date of Publication: 1 May 2018
  12. Aggarwal S., Topaloglu O., Kumar S., Real world evidence for effectiveness of biologics for rheumatoid arthritis: Systematic literature review of population based registry studies, Value in Health (2018) 21 Supplement 1 (S192). Date of Publication: 1 May 2018
  13. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay and costs in patients with hepatocellular carcinoma (HCC): Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S34). Date of Publication: 1 May 2018
  14. Aggarwal S., Kumar S., Topaloglu O., Hospitalization lenght of stay and costs in patients with multiple myeloma: Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S34). Date of Publication: 1 May 2018
  15. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay and costs in patients with chronic lymphoid leukemia: Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S24). Date of Publication: 1 May 2018
  16. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay and costs in patients with peripheral T-cell lymphoma (PTCL): Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S34). Date of Publication: 1 May 2018
  17. Aggarwal S., Topaloglu O., Kumar S., Trends in HTA submissions for rare diseases: Insights from review of nice's highly specialized technology (HST) assessment reports, Value in Health (2018) 21 Supplement 1 (S264-S265). Date of Publication: 1 May 2018
  18. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay and costs in patients with hereditary angioedema: Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S255). Date of Publication: 1 May 2018
  19. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay and costs in patients with primary immunodeficiency: Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S255). Date of Publication: 1 May 2018
  20. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay and costs in endometriosis: Analysis of US national in-patient data for 2015, Value in Health (2018) 21 Supplement 1 (S143). Date of Publication: 1 May 2018
  21. Aggarwal S., Topaloglu O., Kumar S., Role of patient assistance program (PAP) in market access and outcomes: Insights from systematic literature review (2013-2017), Value in Health (2018) 21 Supplement 1 (S99-S100). Date of Publication: 1 May 2018
  22. Aggarwal S., Kumar S., Topaloglu O., Trends in hospitalization lenght of stay, seasonality and costs in patients with respiratory syncytial virus infection: Analysis of US national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses, Value in Health (2018) 21 Supplement 1 (S154). Date of Publication: 1 May 2018
  23. Aggarwal S., Topaloglu O., Kumar S., Cost effectiveness of anti-PD-1/PD-L1 treatments: Systematic review of published studies, Value in Health (2018) 21 Supplement 1 (S29). Date of Publication: 1 May 2018
  24. Aggarwal S., Kumar S., Topaloglu O., Burden of hospitalization in lung cancer patients with brain metastases: Analysis of us national in-patient data for 2015 using ICD-9 and ICD-10 diagnoses, Value in Health (2018) 21 Supplement 1 (S23). Date of Publication: 1 May 2018
  25. Richardson P.G., Aggarwal S., Topaloglu O., Villa K., Corbacioglu S., Pooled analysis of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation or chemotherapy without hematopoietic stem cell transplantation, Journal of Oncology Pharmacy Practice (2018) 24:2 Supplement 1 (18-19). Date of Publication: 1 Mar 2018
  26. Caroff S.N., Aggarwal S., Yonan C., Treatment of tardive dyskinesia with tetrabenazine or valbenazine: A systematic review, Journal of Comparative Effectiveness Research (2018) 7:2 (135-148). Date of Publication: 1 Feb 2018
  27. Colombel J.-F., Ungaro R., Aggarwal S., Topaloglu O., Skup M., Lee W.-J., Efficacy and safety of early biologic treatment of Crohn's disease in adult and paediatric patients: A systematic review, Journal of Crohn's and Colitis (2018) 12 Supplement 1 (S461). Date of Publication: 1 Feb 2018
  28. Richardson P.G., Aggarwal S., Topaloglu O., Villa K., Corbacioglu S., Pooled analysis of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT, Blood (2017) 130 Supplement 1. Date of Publication: 1 Dec 2017
  29. Caroff S.M., Aggarwal S., Yonan C., Feasibility of a comparative meta-analysis of VMAT2 inhibitors for the treatment of tardive dyskinesia, Value in Health (2017) 20:5 (A189). Date of Publication: 1 May 2017
  30. Caroff S., Aggarwal S., Yonan C., Systematic review of valbenazine and tetrabenazine for treatment of tardive dyskinesia, Journal of Managed Care and Specialty Pharmacy (2017) 23 3-A SUPPL. (S60). Date of Publication: 1 Mar 2017
  31. Erman M., Aggarwal S., Topaloglu O., Bujanover S., Black J., Villa K.F., Efficacy of sodium oxybate for treatment of excessive daytime sleepiness in narcolepsy: Meta-analysis of randomized controlled trials, Sleep (2017) 40 Supplement 1 (A249). Date of Publication: 2017
  32. Aggarwal S., Kumar S., Topaloglu O., Insights from analysis of formulary coverage trends for generics with high price increases, Journal of Managed Care and Specialty Pharmacy (2016) 22 10-A SUPPL. (S93). Date of Publication: 1 Oct 2016
  33. Aggarwal S., Kumar S., Topaloglu H., Harvoni access and utilization trends in fifty medicaid programs in the United States, Value in Health (2016) 19:3 (A318). Date of Publication: May 2016
  34. Aggarwal S., Kumar S., Topaloglu H., Trends in design of pivotal phase III clinical trials for alpha 1 anti trypsin deficiency disorder, Value in Health (2016) 19:3 (A102-A103). Date of Publication: May 2016
  35. Aggarwal S., Kumar S., Topaloglu H., Latest trends in design of pivotal phase III clinical trials for hemophilia A And B, Value in Health (2016) 19:3 (A103). Date of Publication: May 2016
  36. Aggarwal S., Kumar S., Topaloglu H., Latest trends in design of pivotal phase III clinical trials for partial onset of seizures, Value in Health (2016) 19:3 (A103). Date of Publication: May 2016
  37. Aggarwal S., Kumar S., Topaloglu H., Latest trends in design of pivotal phase III clinical trials for peripheral T-Cell lymphoma, Value in Health (2016) 19:3 (A104). Date of Publication: May 2016
  38. Aggarwal S., Kumar S., Topaloglu H., Trends in design of pivotal phase III clinical trials for cluster headache disorder, Value in Health (2016) 19:3 (A104). Date of Publication: May 2016
  39. Aggarwal S., Kumar S., Topaloglu H., Latest trends in design of clinical trials for real-world health economic evidence generation, Value in Health (2016) 19:3 (A105). Date of Publication: May 2016
  40. Aggarwal S., Topaloglu H., Systematic review of design of latest real-world observational studies in multiple myeloma, Value in Health (2016) 19:3 (A140-A141). Date of Publication: May 2016
  41. Aggarwal S., Kumar S., Topaloglu H., Price increases for generics imposing new market access challenge: Insights from analysis of formulary coverage trends for generics, Value in Health (2016) 19:3 (A260). Date of Publication: May 2016
  42. Aggarwal S., Topaloglu H., Trends in ER visits due to hyperkalemia in the United States, Value in Health (2016) 19:3 (A42). Date of Publication: May 2016
  43. Aggarwal S., Kumar S., Topaloglu H., Systematic review of burden of hyperkalemia due to angiotensin enzyme converting inhibitors, Value in Health (2016) 19:3 (A42). Date of Publication: May 2016
  44. Aggarwal S., Kumar S., Topaloglu H., Analysis of access to harvoni for medicare patients in all fifty states in the US, Value in Health (2016) 19:3 (A168). Date of Publication: May 2016
  45. Aggarwal S., Kumar S., Topaloglu H., Patient access to oral breakthrough cancer drugs in The United States, Value in Health (2016) 19:3 (A168). Date of Publication: May 2016
  46. Aggarwal S., Kumar S., Topaloglu H., Bayesian network meta-analysis on prevention of stroke for patent foramen ovale closure, Value in Health (2016) 19:3 (A298). Date of Publication: May 2016
  47. Disease Aggarwal S., Kumar S., Topaloglu H., Latest trends in design of pivotal clinical trials for huntington's, Value in Health (2016) 19:3 (A77). Date of Publication: May 2016
  48. Aggarwal S., Kumar S., Topaloglu H., Bayesian network meta-analysis to assess comparative effectiveness of beta-blockers in patients with heart failure and reduced ejection fraction, Value in Health (2016) 19:3 (A2). Date of Publication: May 2016
  49. Aggarwal S., Topaloglu H., Systematic review of cost-effectiveness analyses of ultra-orphan therapies, Value in Health (2016) 19:3 (A247). Date of Publication: May 2016
  50. Aggarwal S., Kumar S., Topaloglu H., Market access insights from review of us formulary coverage trends for top 100 selling drugs, Value in Health (2016) 19:3 (A280). Date of Publication: May 2016
  51. Aggarwal S., Kumar S., Topaloglu H., Analysis of essential health benefit benchmark plans in the United States, Value in Health (2016) 19:3 (A280). Date of Publication: May 2016
  52. Aggarwal S., Kumar S., Topaloglu H., Trends in design, conduct, and outcomes measures for patient registries for multiple sclerosis, Value in Health (2016) 19:3 (A70). Date of Publication: May 2016
  53. Aggarwal S., Kumar S., Topaloglu H., Latest trends in design of clinical trials for stroke treatment with stem cells, Value in Health (2016) 19:3 (A74-A75). Date of Publication: May 2016
  54. Wallick C., Aggarwal S., Yonan C., Shulman K.J., Rapid relief of pain in episodic migraine was associated with lower self-reported disability and lower rates of migraine-associated symptoms: A secondary analysis of the compass trial, Value in Health (2016) 19:3 (A60). Date of Publication: May 2016
  55. Velez F., Aggarwal S., Cost-effectiveness of eslicarbazepine acetate monotherapy in partial-onset epilepsy, Journal of Managed Care and Specialty Pharmacy (2016) 22 4-A SUPPL. (S75-S76). Date of Publication: 1 Apr 2016
  56. Wallick C., Aggarwal S., Yonan C., Shulman K., Rapid relief of pain in episodic migraine is associated with lower self-reported disability and lower rates of migraine associated symptoms: A secondary analysis of the COMPASS trial, Journal of Managed Care and Specialty Pharmacy (2016) 22 4-A SUPPL. (S76). Date of Publication: 1 Apr 2016
  57. Aggarwal S., Topaloglu H., Kumar S., Systematic review of cost effectiveness of ultra-orphan therapies, Value in Health (2015) 18:7 (A533). Date of Publication: November 2015
  58. Aggarwal S., Kumar S., Topaloglu H., Systematic review of FDA breakthrough therapy designated products, Value in Health (2015) 18:7 (A541). Date of Publication: November 2015
  59. Aggarwal S., Kumar S., Topaloglu H., Comparison of network meta-analysis and traditional meta-analysis for prevention of relapses in multiple sclerosis, Value in Health (2015) 18:7 (A660). Date of Publication: November 2015
  60. Aggarwal S., Topaloglu H., Kumar S., Systematic review of burden of cutaneous t-cell lymphoma, Value in Health (2015) 18:7 (A438). Date of Publication: November 2015
  61. Aggarwal S., Topaloglu H., Kumar S., Systematic review of burden of pancreatic cancer, Value in Health (2015) 18:7 (A439). Date of Publication: November 2015
  62. Aggarwal S., Topaloglu H., Kumar S., Probiotics significantly reduce mortality in preterm newborns with necrotising enterocolitis: Results of large network meta-analysis, Value in Health (2015) 18:7 (A576). Date of Publication: November 2015
  63. Aggarwal S., Kumar S., Topaloglu H., Network meta-analysis on prevention of stroke for patent foramen ovale closure, Value in Health (2015) 18:7 (A346-A347). Date of Publication: November 2015
  64. Aggarwal S., Topaloglu H., Kumar S., Trends in emergency room visits due to hyperkalemia in the United States, Value in Health (2015) 18:7 (A386). Date of Publication: November 2015
  65. Aggarwal S., Topaloglu H., Kumar S., Systematic review of hyperkalemia due to angiotensin enzyme converting inhibitors, Value in Health (2015) 18:7 (A396). Date of Publication: November 2015
  66. Aggarwal S., Topaloglu H., Kumar S., Systematic review on use of economic evidence in clinical guidelines, Value in Health (2015) 18:7 (A516). Date of Publication: November 2015
  67. Aggarwal S., Topaloglu H., Kumar S., Policy implications of affordable care act on us market access, Value in Health (2015) 18:7 (A518). Date of Publication: November 2015
  68. Aggarwal S., Kumar S., Topaloglu H., Review of patient reported outcomes in glaucoma, Value in Health (2015) 18:7 (A426). Date of Publication: November 2015
  69. Aggarwal S., Kumar S., Topaloglu H., Overview of nub process for in-patient drugs and devices in German, Value in Health (2015) 18:7 (A546). Date of Publication: November 2015
  70. Aggarwal S., Topaloglu H., Kumar S., Impact of essential health benefit benchmark plans on us market access, Value in Health (2015) 18:7 (A546). Date of Publication: November 2015
  71. Aggarwal S., Topaloglu H., Kumar S., Ultra orphan and cancer drug pricing trends in the us and the UK, Value in Health (2015) 18:7 (A547). Date of Publication: November 2015
  72. Aggarwal S., Topaloglu H., Kumar S., Network meta-analysis to assess comparative effectiveness of beta-blockers in patients with heart failure and reduced ejection fraction, Value in Health (2015) 18:7 (A375). Date of Publication: November 2015
  73. Aggarwal S., Topaloglu J., Kumar S., Comprehensive review of managed care formulary access trends for top 100 selling drugs, Journal of Managed Care and Specialty Pharmacy (2015) 21 10-a SUPPL. (S11-S12). Date of Publication: 1 Oct 2015
  74. Wallick C., Shulman K., Siegert S., Aggarwal S., Yonan C., The treatment evidence disconnect between what migraine patients want and what is reported in trial literature: A systematic literature review of rapid relief outcomes in migraine therapy trials, Journal of Managed Care and Specialty Pharmacy (2015) 21 10-a SUPPL. (S49). Date of Publication: 1 Oct 2015
  75. Aggarwal S., Topaloglu H., Impact of 2014 essential health benefit benchmark plans on us managed care, Value in Health (2015) 18:3 (A73). Date of Publication: May 2015
  76. Aggarwal S., Topaloglu H., Kumar S., Comparative effectiveness, approval rates and pricing of drugs with FDA 's breakthrough therapy designations, Value in Health (2015) 18:3 (A87). Date of Publication: May 2015
  77. Topaloglu H., Aggarwal S., Impact of new changes due to affordable care act on us market access, Value in Health (2015) 18:3 (A88). Date of Publication: May 2015
  78. Aggarwal S., Kumar S., Topaloglu H., Overview and importance of nub process for market access of inpatient drugs and devices in Germany, Value in Health (2015) 18:3 (A89). Date of Publication: May 2015
  79. Aggarwal S., Topaloglu H., Kumar S., Patient reported outcomes in Glaucoma a Systematic review, Value in Health (2015) 18:3 (A184). Date of Publication: May 2015
  80. Aggarwal S., Topaloglu H., Kumar S., Systematic review of epidemiology and burden of pancreatic cancer, Value in Health (2015) 18:3 (A198-A199). Date of Publication: May 2015
  81. Aggarwal S., Topaloglu H., Systematic review of epidemiology and burden of cutaneous T-cell lymphoma, Value in Health (2015) 18:3 (A199). Date of Publication: May 2015
  82. Aggarwal S., Kumar S., Topaloglu H., Trends in use of health economic evidence for developing clinical guidelines, Value in Health (2015) 18:3 (A99). Date of Publication: May 2015
  83. Aggarwal S., Topaloglu H., Kumar S., Systematic review of cost effectiveness of ultra-orphan therapies: Lesson learned from published HTAs and studies, Value in Health (2015) 18:3 (A8-A9). Date of Publication: May 2015
  84. Kumar S., Aggarwal S., Topaloglu H., Comparison of ultra orphan and cancer drug pricing in the us and the UK, Value in Health (2015) 18:3 (A305). Date of Publication: May 2015
  85. Diamantidis C.J., Ginsberg J.S., Yoffe M., Lucas L., Prakash D., Aggarwal S., Fink W., Becker S., Fink J.C., Remote usability testing and satisfaction with a mobile health medication inquiry system in CKD, Clinical Journal of the American Society of Nephrology (2015) 10:8 (1364-1370). Date of Publication: 7 Aug 2015
  86. Lin H.M., Suri A., Webb I.J., Aggarwal S., Relationships between food effects, patient adherence to treatment, and pharmacokinetics of oral anticancer drugs, Journal of Clinical Oncology (2014) 32:15 SUPPL. 1. Date of Publication: 20 May 2014
  87. Aggarwal S., Kumar S., Segal J., Meta-analysis of safety of dabigatran and warfarin for atrial fibrillation, Value in Health (2014) 17:3 (A105-A106). Date of Publication: May 2014
  88. Aggarwal S., Topaloglu H., Kumar S., Adjusting budget impact model based on new changes due to affordable care Act, Value in Health (2014) 17:3 (A1). Date of Publication: May 2014
  89. Aggarwal S., Topaloglu H., Segal J., Meta-analysis of efficacy of etanercept for psoriatic arthritis, Value in Health (2014) 17:3 (A42). Date of Publication: May 2014
  90. Aggarwal S., Topaloglu H., Kumar S., Cost of in-patient hospitalizations for chronic kidney disease in the United States, Value in Health (2014) 17:3 (A293). Date of Publication: May 2014
  91. Aggarwal S., Topaloglu H., Systematic review of cost effectiveness of top selling products, Value in Health (2014) 17:3 (A21). Date of Publication: May 2014
  92. Aggarwal S., Topaloglu H., Need for subgroup cost effectiveness analyses for health technology assessments, Value in Health (2014) 17:3 (A27). Date of Publication: May 2014
  93. Aggarwal S., McGrane M., Trends in use of economic evidence by clinical guidelines, Value in Health (2014) 17:3 (A30). Date of Publication: May 2014
  94. Aggarwal S., Segal J., Patient reported outcomes in castration-resistant prostate cancer, Value in Health (2014) 17:3 (A94). Date of Publication: May 2014
  95. Aggarwal S., Topaloglu H., Oncology pricing trends in the United States and the United Kingdom (2011-2013), Value in Health (2014) 17:3 (A99). Date of Publication: May 2014
  96. Aggarwal S., Topaloglu H., Meta-analysis of efficacy of romiplostim for immune idiopathic thrombocytopenia, Value in Health (2014) 17:3 (A224-A225). Date of Publication: May 2014
  97. Aggarwal S., Topaloglu H., Is FDA's breakthrough therapy designation a game-changing trend for patients and payers?, Value in Health (2014) 17:3 (A10). Date of Publication: May 2014
  98. Roy S., Ghosh S.K., Aggarwal S., Yoo A.C., Meta-analysis of anastomotic leak rates following hand-sewn suture versus stapled anastomoses during right colon surgery, Value in Health (2014) 17:3 (A67-A68). Date of Publication: May 2014
  99. Aggarwal S.R., What's fueling the biotech engine-2012 to 2013, Nature Biotechnology (2014) 32:1 (32-39). Date of Publication: January 2014
  100. Aggarwal S.R., A survey of breakthrough therapy designations, Nature Biotechnology (2014) 32:4 (323-330). Date of Publication: April 2014
  101. Aggarwal S., Topaloglu H., Kumar S., Import ance of subgroup analyses for health technology assessments, Value in Health (2013) 16:7 (A462). Date of Publication: November 2013
  102. Aggarwal S., McGrane M., Topaloglu H., Systematic review on use of economic evidence by clinical guidelines, Value in Health (2013) 16:7 (A485-A486). Date of Publication: November 2013
  103. Aggarwal S., Kumar S., Topaloglu H., Novel market access models for cancer drugs, Value in Health (2013) 16:7 (A428). Date of Publication: November 2013
  104. Aggarwal S., Segal J., Topaloglu H., A systematic review of patient reported outcomes in glaucoma, Value in Health (2013) 16:7 (A509). Date of Publication: November 2013
  105. Aggarwal S., Segal J., Topaloglu H., Systematic review of patient reported outcomes in chronic myeloid leukemia, Value in Health (2013) 16:7 (A420-A421). Date of Publication: November 2013
  106. Aggarwal S., Segal J., Kumar S., Patient reported outcomes in metastatic castration-resistant prostate cancer, Value in Health (2013) 16:7 (A421). Date of Publication: November 2013
  107. Aggarwal S., Topaloglu H., Meta-analysis of efficacy of etanercept for treatment of psoriatic arthritis, Value in Health (2013) 16:7 (A555). Date of Publication: November 2013
  108. Aggarwal S., Topaloglu H., Meta-analysis of efficacy of romiplostim for treatment of immune idiopa thic thrombocytopenia, Value in Health (2013) 16:7 (A378). Date of Publication: November 2013
  109. Aggarwal S., Segal J., Meta-analysis of safety of dabigatran and warfarin for treatment of atrial fibrillation, Value in Health (2013) 16:7 (A515). Date of Publication: November 2013
  110. Aggarwal S., Topaloglu H., In-patient hospitalizations for chronic kidney disease in the United States, Value in Health (2013) 16:7 (A631-A632). Date of Publication: November 2013
  111. Aggarwal S., Topaloglu H., Kumar S., Segal J., McGrane M., Trends in use of health economic evidence for developing clinical guidelines, Value in Health (2013) 16:3 (A245). Date of Publication: May 2013
  112. Aggarwal S., Segal J., Messenger M., Patient reported outcomes in chronic myeloid leukemia: A systematic review, Value in Health (2013) 16:3 (A147). Date of Publication: May 2013
  113. Aggarwal S., Segal J., Messenger M., Patient reported outcomes in metastatic castration-resistant prostate cancer: A systematic review, Value in Health (2013) 16:3 (A149). Date of Publication: May 2013
  114. Aggarwal S., Topaloglu H., Kumar S., Cancer drug pricing trends in the united states and the united kingdom (2011-2013), Value in Health (2013) 16:3 (A150). Date of Publication: May 2013
  115. Aggarwal S., Topaloglu H., Messenger M., Novel reimbursement models for cancer drug market access (2010- 2013), Value in Health (2013) 16:3 (A153). Date of Publication: May 2013
  116. Aggarwal S., Topaloglu H., Messenger M., Meta-analysis for safety of dabigatran and warfarin for treatment of atrial fibrillation, Value in Health (2013) 16:3 (A274). Date of Publication: May 2013
  117. Aggarwal S., Segal J., Messenger M., Patient reported outcomes in glaucoma a systematic review, Value in Health (2013) 16:3 (A178). Date of Publication: May 2013
  118. Aggarwal S., Topaloglu H., Messenger M., Meta-analysis for efficacy of etanercept for treatment of psoriatic arthritis, Value in Health (2013) 16:3 (A219). Date of Publication: May 2013
  119. Aggarwal S., Topaloglu H., Messenger M., Meta-analysis for efficacy of romiplostim for treatment of immune idiopathic thrombocytopenia, Value in Health (2013) 16:3 (A112-A113). Date of Publication: May 2013
  120. Aggarwal S., Topaloglu H., Novel electronic patient reported outcomes tool for prostate cancer patients, Value in Health (2013) 16:3 (A147). Date of Publication: May 2013
  121. Aggarwal S., Segal J., Systematic review of anti-VEGF therapies for metastatic colorectal cancer, Value in Health (2013) 16:3 (A128). Date of Publication: May 2013
  122. Aggarwal S., Topaloglu H., Budget impact model for cutaneous t-cell lymphoma, Value in Health (2013) 16:3 (A132-A133). Date of Publication: May 2013
  123. Aggarwal S., Topaloglu H., Role of subgroup analyses for health technology assessments, Value in Health (2013) 16:3 (A264-A265). Date of Publication: May 2013
  124. Aggarwal S., Messenger M., Trends in cost effectiveness of high budget impact products, Value in Health (2013) 16:3 (A19-A20). Date of Publication: May 2013
  125. Aggarwal S., Topaloglu H., In-patient hospitalization trends for chronic kidney disease in the United States, Value in Health (2013) 16:3 (A181). Date of Publication: May 2013
  126. Aggarwal S., Topaloglu H., Reimbursement and market access of multiple sclerosis products in the united states, Value in Health (2013) 16:3 (A109). Date of Publication: May 2013
  127. Aggarwal S., Messenger M., Pricing and reimbursement of targeted cancer therapies in russia (2011-2012), Value in Health (2013) 16:3 (A260). Date of Publication: May 2013
  128. Diamantidis C.J., Zuckerman M., Fink W., Aggarwal S., Prakash D., Fink J.C., Usability testing and acceptance of an electronic medication inquiry system for CKD patients, American Journal of Kidney Diseases (2013) 61:4 (644-646). Date of Publication: April 2013
  129. Aggarwal S., What's fueling the biotech engine-2011 to 2012, Nature Biotechnology (2012) 30:12 (1191-1197). Date of Publication: December 2012
  130. Aggarwal S., Systematic review of non-interferon based regimens for chronic hepatitis c treatment, Value in Health (2012) 15:7 (A385). Date of Publication: November 2012
  131. Aggarwal S., 2010-2012 global health care reforms and their impact on pricing, access and health outcomes strategy, Value in Health (2012) 15:7 (A291). Date of Publication: November 2012
  132. Aggarwal S., Role of subgroup analyses for technology assessment and coverage decisions, Value in Health (2012) 15:7 (A291). Date of Publication: November 2012
  133. Aggarwal S., France market access: Review of 2011-2012 assessments by transparency committee, Value in Health (2012) 15:7 (A294-A295). Date of Publication: November 2012
  134. Aggarwal S., Access, uptake and utilization management of multiple sclerosis products in the United States, Value in Health (2012) 15:7 (A559). Date of Publication: November 2012
  135. Aggarwal S., Comparison of cancer drug prices in the United States and the UK, Value in Health (2012) 15:7 (A278). Date of Publication: November 2012
  136. Aggarwal S., Emerging drug reimbursement models: Lessons and implications from cancer drug access schemes, Value in Health (2012) 15:7 (A298-A299). Date of Publication: November 2012
  137. Aggarwal S., Review of cost effectiveness studies of high budget impact drugs (2007-2012), Value in Health (2012) 15:7 (A309). Date of Publication: November 2012
  138. Aggarwal S., New pricing dynamics in big five EU: Case study of biosimilar GM-CSF products, Value in Health (2012) 15:7 (A310). Date of Publication: November 2012
  139. Aggarwal S., Emerging market access trends: Pricing and coverage of targeted cancer therapies in Russia (2011-2012), Value in Health (2012) 15:7 (A433). Date of Publication: November 2012
  140. Aggarwal S., Systematic review of clinical efficacy and safety outcomes of anti-vegf therapies for metastatic colorectal cancer, Value in Health (2012) 15:4 (A210). Date of Publication: June 2012
  141. Aggarwal S., Developing budget impact model for rare diseases: Case in point cutaneous T-cell lymphoma, Value in Health (2012) 15:4 (A212). Date of Publication: June 2012
  142. Aggarwal S., Trends in rate and cost of hospitalizations due to chronic kidney disease (CKD) in the united states, Value in Health (2012) 15:4 (A154). Date of Publication: June 2012
  143. Aggarwal S., Electronic patient reported outcomes and data tool for chronic disease management (PROCDIM): Case in point prostate cancer, Value in Health (2012) 15:4 (A201). Date of Publication: June 2012
  144. Aggarwal S., Oncology drug prices in the United States and the United Kingdom: Implications for pricing strategy and drug access, Value in Health (2012) 15:4 (A232). Date of Publication: June 2012
  145. Aggarwal S., Systematic review of interferon free based regimens for chronic Hepatitis C treatment, Value in Health (2012) 15:4 (A237). Date of Publication: June 2012
  146. Aggarwal S., Cost effectiveness trends of high budget impact drugs (2006-2012), Value in Health (2012) 15:4 (A5). Date of Publication: June 2012
  147. Aggarwal S., Impact of 2009-2011 global health care reforms on pricing, access and health outcomes strategy, Value in Health (2012) 15:4 (A12). Date of Publication: June 2012
  148. Aggarwal S., What's fueling the biotech engine-2010 to 2011, Nature Biotechnology (2011) 29:12 (1083-1089). Date of Publication: December 2011
  149. Aggarwal S., Novel patient reported outcomes and data tool for chronic disease management (PROCDIM): Case in point prostate cancer, Value in Health (2011) 14:7 (A421-A422). Date of Publication: November 2011
  150. Aggarwal S., Trends in rate and cost of hospitalizations due to chronic kidney disease (CKD) in the united states, Value in Health (2011) 14:7 (A332-A333). Date of Publication: November 2011
  151. Aggarwal S., Cancer drug prices in the United States and the United Kingdom: Implications for pricing strategy and drug access, Value in Health (2011) 14:7 (A466). Date of Publication: November 2011
  152. Aggarwal S., Review of cost effectiveness models of high budget impact drugs, Value in Health (2011) 14:7 (A361). Date of Publication: November 2011
  153. Aggarwal S., Novel drug reimbursement models: Lessons and implications from cancer drug access schemes, Value in Health (2011) 14:7 (A361). Date of Publication: November 2011
  154. Aggarwal S., Impact of amnog on pharmaceutical pricing trends in Germany, Value in Health (2011) 14:7 (A362). Date of Publication: November 2011
  155. Aggarwal S., Systematic review of non-interferon based regimens for chronic hepatitis C treatment, Value in Health (2011) 14:7 (A267). Date of Publication: November 2011
  156. Aggarwal S., Systematic review of clinical efficacy and safety outcomes of anti-angiogenic therapies for metastatic colorectal cancer, Value in Health (2011) 14:7 (A436). Date of Publication: November 2011
  157. Aggarwal S., Budget impact model for rare cancer treatment: Case in point cutaneous T-cell lymphoma, Value in Health (2011) 14:7 (A438). Date of Publication: November 2011
  158. Aggarwal S., Global health care reforms and pricing, access and health outcomes strategy, Value in Health (2011) 14:7 (A351-A352). Date of Publication: November 2011